FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply

View Preview

Pfizer Inc.'s (NYSE:PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna Inc. (NASDAQ:MRNA) to step in to help fill potential gaps.

"We are working to ensure there will be sufficient supply," said Chris Ridley, a Moderna spokesperson.

See what PFE stock is doing here.

According to an email from the National Center for Immunization and Respiratory Diseases obtained by The Guardian, the FDA recently told Pfizer it may not renew the emergency use authorization for its pediatric COVID-19 vaccine for the 2025 respiratory season.

Also Read: RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: ‘We’re Prioritizing Safer, Broader Strategies’

The move could remove the only COVID-19 vaccine available to all children under five from the market. The vaccine is currently authorized for ...